2010 Guidelines Part 9: Post–Cardiac Arrest Care: Writing Group Disclosures

Writing Group Member Employment Research Grant Other Research Support Speakers’ Bureau/Honoraria Ownership Interest Consultant/Advisory Board Other
Mary Ann Peberdy Virginia Commonwealth University–Professor of Medicine & Emergency Medicine None None None None None None
Clifton W. Callaway University of Pittsburgh School of Medicine–Associate Professor; UPMC Health System–Physician Grants to University of Pittsburgh: NHLBI-Resuscitation Outcomes Consortium HRSA-Development and Dissemination of Program
Tools for Uncontrolled Donation After Cardiac Death (UDCD)
*Loan of an Arctic Sun cooling device (without disposables) to human physiology laboratory for experiments on hypothermia by
Medivance, Inc.
None Co-inventor on patent about ventricular fibrillation waveform analysis, licensed by University of Pittsburgh to Medtronic
ERS, Inc.
None None
Robert W. Neumar University of Pennsylvania–Associate Professor of Emergency Medicine Funding Source: NIH/NINDS Grant Number: R21 NS054654 Funding Period 06/01/07 to 06/31/2010 Role on Project: Principal Investigator
Title: Optimizing Therapeutic Hypothermia After Cardiac Arrest Description: The goal of this project is to evaluate how the
onset and duration of therapeutic hypothermia after cardiac arrest impacts survival and neuroprotection
None None None None None
Romergryko G. Geocadin Johns Hopkins University School of Medicine–Associate Professor of Neurology, Anesthesiology-Critical Care Medicine and Neurosurgery NIH RO1 Grant: “Consequence of Cardiac Arrest: Brain Injury” *NIH R44 Grant: “Cortical Injury Monitor Phase IIB” None *Academic Grand Rounds American Academy of Neurology None None *Guest Editor: Neurology Clinics, Emergency Medicine Clinics, and Seminars in Neurology
Janice L. Zimmerman The Methodist Hospital Physician Organization–Head, Critical Care Division and Director, MICU None None *Society of Critical Care Medicine American College of Chest Physicians Center for Biomedical Communications None None *Callaway and Associates Andrews and Kurth
Michael Donnino Harvard Medical Faculty Physicians–Physician Corticosteroids in Post-cardiac Arrest Patients [Scientist Development Grant, American Heart Association] Thiamine as a Metabolic
Resuscitator in Septic Shock [Pending] *Thiamine Deficiency in Septic Shock [completed, NIH through Harvard Medical School] Statin Therapy in Sepsis [Eleanor Shores
Grant-nonindustry]
None None None None None
Andrea Gabrielli University of Florida–Professor of Anesthesiology and Surgery NIH-Biomarkers and Traumatic Brain Injury None None None None None
Scott M. Silvers Mayo Clinic Florida–Chair, Department of Emergency Medicine None None None None None None
Arno L. Zaritsky Children’s Hospital of the King’s Daughters–Sr. VP for Clinical Services None None None None *Data Safety Monitoring Board for NIH-sponsored clinical trial of therapeutic hypothermia after pediatric cardiac arrest None
Raina Merchant University of Pennsylvania–Research fellow None None None None None None
Terry L. Vanden Hoek University of Chicago–Associate Professor *Principal Investigator 09/06/04–04/30/10 DOD/Office of Naval Research $885 639 Proteomic Development of Molecular Vital Signs:
Mapping a Mitochondrial Injury Severity Score to Triage and Guide Resuscitation of Hemorrhagic Shock. This research grant
is awarded to the University of Chicago
None None *Hypothermia Induction Patents (3 approved, 3 pending) no income None None
Steven L. Kronick University of Michigan Health System Healthcare institution Assistant Professor None None None None None *Expert Witness: Reviewed a single case for an attorney. Less than 4 hours work total
  • This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts
    of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and
    submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period,
    or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity,
    or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less
    than “significant” under the preceding definition.

  • * Modest.

  • Significant.